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Background:Pulmonary embolism (PE) is a life-threatening condition that is associatedwith the long-term sequelae of chronic
pulmonary hypertension. Prior experimental work has suggested that post-PE inflammation is accompanied by pulmonary
artery intimal hyperplasia. This study evaluated the effect of the thrombus and tested the hypothesis that thrombolytic,
antiplatelet, and anticoagulant agents would decrease pulmonary injury.
Methods:Male Sprague-Dawley rats (n 267) underwent laparotomy and temporary clip occlusion of the infrarenal inferior
vena cava for the formation of endogenous thrombus or placement of an inert silicone “thrombus.” Two days later, repeat
laparotomy was performed, the clip removed, and the thrombus or silicone plug was embolized to the lungs. The endogenous
thrombus group received normal saline, low-molecular-weight heparin (LMWH), tissue plasminogen activator (tPA), or a
gIIB/IIIA antagonist (abciximab). Lung tissue was harvested at various times over 21 days and assayed for total collagen,
monocyte chemoattractant protein-1 (MCP-1), interleukin-13 (IL-13), and transforming growth factor- (TGF-). Fixed
sectionswere stainedwith trichrome for intimal hyperplasia determination andED-1monocytes and-actin-positive staining.
Results: The overall survival for rats undergoing PEwas 90%, was not affected by treatment, and 84% of all PE localized to the
right pulmonary artery. The PE significantly reduced PaO2 in all groups. Compared with controls, the silicone emboli group
had an increased level of IL-13 on day 1, an increased level ofMCP-1 on day 4, and an increase in the levels of all inflammatory
mediators on day 14 (P < .05). Accompanying these differences were greater pulmonary artery intimal hyperplasia at days 4
and 21 in the silicone group compared with controls (P < .05). LMWH treatment in the thrombus of PE rats significantly
decreased IL-13 levels at all time points, whereas treatment with abciximab or tPA significantly increased IL-13 levels
compared with controls. TGF- levels were significantly increased by LMWH at day 4 and 14, and abciximab was associated
with lower TGF- at day 14. Only LMWHwas associated with less pulmonary artery intimal hyperplasia at day 14 compared
with controls and the other treatment groups.
Conclusions: Persistent pulmonary artery distention by an inert material is sufficient to invoke significant inflammation
and intimal hyperplasia independent of the thrombus itself. Compared with nontreated PE, LMWH is the only therapy
associated with a significant reduction in late intimal hyperplasia and, with the exception of TGF-, lower profibrotic
growth-factor production. (J Vasc Surg 2006;43:800-8.)
Clinical Relevance: Pulmonary embolism is a highly fatal disease and may be associated with long-term pulmonary
hypertension. Few good animal models exist for this condition, and the aim of this report was to evaluate the role of the
thrombus itself on the pulmonary artery injury and to assess the effect of currently available therapies. Our data suggest
that rapid treatment of pulmonary embolism with low-molecular-weight heparin is associated with least injury response,
and that persistent occlusion of the pulmonary artery is associated with significant injury.From the Department of Surgery, Jobst Vascular Research Laboratory,
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800Pulmonary embolism (PE) is a life-threatening conditionwith
an acute mortality of 30% that is estimated to occur in 3.5 of
every 1000 hospitalized patients.1 Most often, PE arises from
a lower-extremity deep venous thrombosis (DVT) and is a
potential long-term sequelae of pulmonary hypertension,
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DVT and associated PE has decreased with improved anti-
coagulant prophylaxis, little true decrease in incidence has
occurred over the last several years.3 Heparin, in either the
unfractionated or low-molecular-weight form, remains the
mainstay of acute treatment for PE. Clinical trials of sys-
temic thrombolytic therapy have failed to demonstrate a
significant reduction in early mortality and were associated
with a significant risk of bleeding while infused; however,
certain clinical scenarios warrant its use.4,5 Effectiveness of
gIIB/IIIA antiplatelet therapy for acute treatment of PE is
currently unknown, but platelets play an important role in
thrombosis and vascular injury.6
At present, little is known about the pathobiology of
PE at the cellular and molecular level. Resolution of PE in
humans in may take 30 days,7 and is dependent on native
fibrinolytic mechanisms. For example, inhibition of the
urokinase-type plasminogen activator was associated with
increased fibrin in hypoxemic lung tissue.8 The PE may also
cause bilateral pulmonary vasoconstriction and injury out-
side of the affected pulmonary artery (PA) bed.9 Several
large-animal models of PE have been developed, but these
models rely upon exogenously formed thrombus or air
emboli and do not mimic the human clinical disease. Prior
experimental work in our laboratory has shown that
post-PE inflammation is associated with early monocyte
influx, elevatedmonocyte chemotactic protein-1 (MCP-1),
and PA intimal hyperplasia (PAIH).10 Importantly, how
the thrombus itself, and whether currently available thera-
pies affect the PA and distal lung parenchyma is not known.
The aim of this study was (1) to determine the effect
of PA distention independent of the thrombus proper on
PA and lung parenchymal injury, and (2) to determine if
PA and parenchymal injury is affected by currently available
anticoagulant therapies.
METHODS
This study was approved by the University of Michigan
Institutional Animal Care andUse Committee, and all animal
care guidelines were strictly followed. Male Sprague-Dawley
rats (n 224), all approximately 10 weeks old and weighing
300 g (Charles River Laboratories, Wilmington, Mass),
underwent laparotomy under isoflurane inhalational anes-
thesia. Inferior vena cava (IVC) thrombosis was produced
by temporary clip occlusion of the infrarenal IVC and
ligation of IVC tributaries.10 Of these, 27 procedures were
technically unsuccessful, resulting in 197 rats being used
during the course of this study.
A transverse caval venotomy was created above the
confluence of the iliac veins in a separate experiment (n 
40), and a preformed medical-grade silicone plug approxi-
mately 2.38 mm in outer diameter and 3 mm in length
(Tygon, Beaverton, Mich) was placed in the IVC, below
the renal veins, with temporary clip control. We chose a
diameter of 2.38 mm for the silicone plug based upon the
average diameter of thrombus that is created within the
IVC using this model and the average diameter of 2.5 mmfor the rat main pulmonary vein.11 The venotomy was
closed with interrupted 9-0 nylon sutures.
Two days later, a repeat laparotomy was performed, the
clip was removed, and the thrombus or silicone plug was
embolized to the lungs. Of note, silicone was compared with
intravenous tubing and a rubber plug material and found to
generate the least inflammatory cell response when placed in
the subcutaneous position (data not shown).
At the time after embolization and after closure of the
laparotomy, a pulmonary angiography with iodinated con-
trast (Hypaque Parenteral, Amersham Health, Princeton,
NJ) was performed via a left internal jugular approach to
confirm PE and determine the location of the embolus
within the PAs. This allowed identification of affected lung
tissue for analysis. Oxygen saturation measurements were
taken via the ventral tail artery in all rats at the time of the
initial laparotomy, at PE, and at harvest.
Treatment groups received one-time subcutaneous
low-molecular-weight heparin (LMWH) (450 IU/kg, n
27) (Dalteparin, Pharmacia and Upjohn Co., Kalamazoo,
Mich), intravenous tissue plasminogen activator (tPA)
(1 mg/kg, n  27) (Retavase, Centocor, Malvern, Penn),
or the gIIB/IIIA antagonist abciximab (1 mg/kg, n 26)
(Eli Lilly and Co, Indianapolis, Ind) via tail vein injection
immediately after the pulmonary angiography (within 30
minutes after the PE). Doses of the various treatment
agents were derived from the available literature.12-14 No
treated rats died from hemorrhagic complications. Control
rats (n  61) were injected with an equivalent volume of
normal saline either subcutaneously or in the dorsal tail
vein, as appropriate.
At days 1, 4, and 14, the rats were sacrificed, and the
lungs affected with PE and the contralateral lungs were
harvested. The affected lung lobe that was identified on
pulmonary angiogram at the time of embolization was snap
frozen in liquid nitrogen or perfusion-fixed with formalin
for trichrome staining and histologic processing. Lung
tissue from rats that received inert silicone emboli was har-
vested at 1, 4, 14, and 21 days post-emboli. The silicone
emboli were removed from the lung tissue before processing.
The saline-injected control rats used for comparison in the
above two experiments were completed concurrently with
both the silicone inert thrombus and the venous thromboem-
bolism treatment groups. The data from the saline control
Table I. Surgical model outcomes
Outcome
Numbers
(affected/total) Percentage
Successful PE 178/197 90.5
PE in right PA 165/197 84
Unable to embolize thrombus 3/197 1.5
No PE in IVC 9/197 4.5
Death 15/197 7.6
Death from PE 8/15 53
PE, Pulmonary embolism; PA, pulmonary artery; IVC, inferior vena cava.rats were pooled to increase the power of the comparison
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thromboembolism groups.
Collagen and glycosaminoglycan assay. Lung collagen-
glycosaminoglycan content was estimated by a commer-
cially available kit according to manufacturer’s instructions
(BioColor LTD, Belfast, North Ireland).15 This collagen
assay uses a quantitative method by which anionic Sirius red
(Direct Red) dye binds to the side chains of basic amino
acids found in collagen types I to IV. Levels were corrected
to milligrams of protein in the sample.
Histologic analysis and staining. Sections of affected
and contralateral lungs were stained for structural analysis
by trichrome processing as described.15 Then, intimal hy-
perplasia was determined by analyzing five sections of main
PA to account for asymmetry and assessed in a blinded
fashion with the aid of computer imaging quantification.10
Permanent, fixed 10-m sections were analyzed for cel-
lular content by immunohistochemical staining for ED-1
(1:100) (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif)
and smooth muscle -actin (1:200) (Serotec, Raleigh,
NC). A species-specific autoantibodies to collagen (ABC)
alkaline phosphatase or peroxidase kit for rabbit, goat, or
mouse (Vector Laboratories, Inc, Burlingame CA) was
used according to the manufacturer’s instructions for the
secondary antibody and subsequent steps. The slides were
then counterstained with hematoxylin.
For cell counting, a Zeiss Axioplan 2 microscope
(Thornwood, NY) connected to a Zeiss AxioCam HRc
camera was used to obtain 20 images of PE-affected and
Fig 1. Example of pulmonary angiogram and pulmon
embolization of the inferior vena cava thrombus. Note lac
C, Necropsy pulmonary specimens show the thrombus w
different magnifications (B  4 and C  10).contralateral unaffected PAs in -actin– and ED-1–stainedlung tissue slides. Images were analyzed with AxioVision,
release 4.3, (Zeiss) using the automatic measurement pro-
gram, in which -actin– and ED-1–positive staining was
defined, and a field-specific measurement was set to analyze
densitometric mean value red. A measurement frame se-
lecting the PA was defined for each image, and densitomet-
ric values were obtained.
Chemokine/cytokine enzyme-linked immunoab-
sorbent assay. After thawing, the pulmonary tissue was
placed in complete lysis buffer at 0°C (Boehringer Mann-
heim, Indianapolis, Ind), homogenized, sonicated for 10
seconds, centrifuged at 10,000g for 5 minutes, and the
supernatant was collected. Quantification of peptide medi-
ators was normalized to total protein in the sample by a
modified Bradford assay according to the manufacture’s
instructions (Pierce, Inc, Rockford, Ill), with serial dilu-
tions of bovine serum albumin (Sigma Chemical, St. Louis,
Mo) as standards. Lung tissue from the affected and con-
tralateral lung homogenate was assayed for MCP-1, IL-13,
mbolus. A, Pulmonary angiogram in a study rat after
erfusion of the right lower lobe distal to embolus.B and
the right lower lobe branch of the pulmonary artery at
Table II. Inert embolus inflammatory mediators, day 1
Treatment group
(day 1)
IL-13
(ng/mL)
MCP-1
(ng/mL)
TGF-
(ng/mL)
Saline (n  18) 66  6 312  106 232  36
Silicone (n  18) 268  47* 489  69 244  15
All data are presented as mean  SEM.
*P  .05.ary e
k of p
ithinand TGF- by using species-specific primary antibodies as
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kines from 10 pg/mL to 100 ng/mLwith a sensitivity50
pg/mL.
Statistical analysis. All data are presented as mean 
SEM. Comparisons between treated and control groups
were done with analysis of variance and secondary Stu-
dent’s t test orMann-Whitney rank sum test where the data
were not normally distributed. SigmaStat, version 2.03,
statistical software (SPSS, Chicago Ill) was used to calculate
probability values.
RESULTS
The overall survival for the 267 rats undergoing PE was
90% and was not affected by treatment. Most PE were
localized to the right PA (Table I, Fig 1). PaO2 measure-
ments at the time of initial laparotomy and at lung harvest
were similar between all groups at 95% to 97%. Mean PaO2
for the treated groups at the time of PE was 88% for saline,
87% for LMWH, 86% for abciximab, 86% for tPA, and 90%
for rats undergoing silicone PE (P  .05 compared with
baseline PaO2) (PNS between all groups). No significant
differences in PE presence and resolution were found
amongst the treatment groups at the time points analyzed,
with all fully lysed by 4 days.
Effects of inert pulmonary emboli on lung injury
Day 1 results. In the rats treated with inert silicone
emboli, IL-13 levels were markedly elevated at day 1 com-
pared with controls that underwent venous thromboembo-
lism (P  .001). MCP-1 and TGF- level were similar
between groups at this time point (Table II).
Day 4 results. At day 4, IL-13, TGF-, and lung
collagen levels in affected lung tissue were similar between
silicone and thrombi emboli groups (Table III). MCP-1
was elevated twofold in the silicone emboli group com-
pared with controls (P  .002).
Day 14 results. At day 14 after PE, IL-13 was signifi-
Table III. Inert embolus inflammatory mediators and col
Treatment group (day 4) IL-13 (ng/mL) MCP
Saline (n  19) 90  8 4
Silicone (n  12) 98  16 9
IL-13, Interleukin-13; MCP-1, monocyte chemotactic protein-1; TGF-, tr
All data are presented as mean  SEM.
*P  .05.
Table IV. Inert embolus inflammatory mediators and coll
Treatment group (day 14) IL-13 (ng/mL) MCP
Saline (n  24) 92  7 3
Silicone (n  10) 153  24* 8
IL-13, Interleukin-13; MCP-1, monocyte chemotactic protein-1; TGF-, tr
All data are presented as mean  SEM.
*P  .05.cantly elevated in rats with silicone emboli compared withthrombus controls (P  .002) (Table IV); MCP-1 and TGF-
were also significantly elevated compared with controls
(P  .004). Although lung collagen trended lower in the
silicone group, this did not reach significance (P  .15).
Pulmonary artery intimal hyperplasia results. PAIH
was evaluated in the silicone and thrombus control PE
groups. At day 4, PAIHwas threefold greater in the silicone
emboli group than in the thrombus group (P  .003). At
day 21 after embolization, the difference between groups was
even greater, nearly fourfold. (P .007). Also, the IHpresent
was qualitatively more asymmetric in the silicone-embolized
rats compared with the other groups (Figs 2 and 3).
Contralateral lung results. In the contralateral unaf-
fected lung at day 1, silicone-treated rats had significantly
elevated levels of IL-13 (282  55 ng/mL vs 87  9
ng/mL, P  .008). There was no difference in IL-13
between the groups at days 4 or 14. There were no differ-
ences in MCP-1 or TGF- between the two groups at any
time point, and total lung collagen was similar between the
silicone and thrombus emboli groups at day 4 and 14. The
amount of PAIH was minimal and not significantly differ-
ent between the unaffected lungs of silicone and thrombus
PE groups at days 1, 4, and 21 (data not shown).
Effect of treatment of pulmonary embolism on
inflammation in the affected lung
Day 1 results. Compared with controls, levels of
IL-13 in the LMWH-treated rats at day 1 were threefold
lower (P  .001) and were nearly twofold greater in
rodents treated with abciximab and tPA (P  .001) (Fig 4).
MCP-1 levels were similar in all groups at day 1 with the
exception of rats treated with tPA, which had significantly
lower levels compared with saline controls (P  .001) (Fig 5).
Day 4 results. At day 4, there were no significant
differences in TGF- levels or PAIH between treatment
groups and control (Figs 2, 6, and 7). The LMWH-treated
rats showed fourfold lower levels of IL-13 compared with
, day 4
g/mL) TGF- (g/mg protein) Lung collagen
241  23 64  8
3* 220  29 70  16
ming growth factor-.
day 14
g/mL) TGF- (g/mg protein) Lung collagen
3 154  14 136  28
16* 231  20* 58  6
ming growth factor-.lagen
-1 (n
0  8
7  1
ansforagen
-1 (n
2 
9 
ansforthe saline-treated rats (P  .001) (Fig 4). IL-13 levels in
al lini
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levels in all groups were similar to the control group with
the exception of abciximab-treated rats. Rats treated with
abciximab showed a 4.2-fold increase in MCP-1 levels
compared with controls (P  .003) (Fig 5). TGF- levels at
day 4 were similar between the saline, abciximab, and tPA
groups, but significantly elevated in the LMWH group
Fig 2. Examples of pulmonary artery intimal hyperplas
nification) of affected pulmonary arteries in (A) day 1
embolus, (C) day 14 low-molecular-weight heparin, a
between the inner most elastic lamina and the endotheli
Fig 3. Pulmonary artery intimal hyperplasia in thrombus and
silicone emboli groups at 4 and 21 days after embolization. The
effects of inert silicone emboli in the affected pulmonary artery
compared with rats with thrombus emboli. Rats undergoing sili-
cone embolization have a greater amount of pulmonary artery
intimal hyperplasia compared with venous thrombus emboliza-
tion. This effect is seen at both 4 and 21 days after embolization.(P  .005) (Fig 7). Lung collagen remained similar be-tween the saline control group and in the tPA and abcix-
imab treatment groups. However, lung collagen was 35%
greater in the LMWH treatment group than in the throm-
presentative trichrome photomicrographs (400 mag-
e-treated intraluminal thrombus, (B) day 21 silicone
) day 14 saline-treated rats. Arrows denote distance
ng.
Fig 4. Interleukin (IL-13) levels in saline control and treatment
rats 1, 4, and 14 days after pulmonary embolism. Graft shows the
effect of treatment with saline, low-molecular weight heparin
(LMWH), abciximab, and tissue plasminogen activator (tPA) on
pulmonary tissue levels of IL-13. Saline, n 18; LMWH, n 10;
abciximab, n  10; and tPA, n  12 for day 1. Saline, n  21;
LMWH, n  10; abciximab, n  10; and tPA, n  10 for day 4.
Saline, n 24; LMWH, n 12; abciximab, n 10; and tPA, n
9 for day 14. *P  .05 compared with saline controls for day1.
#P  .05 compared with saline controls for day 4. ^P  .05
compared with saline controls for day 14.ia. Re
salin
nd (Dbus controls at day 4 (99  12 vs 64  8 g/mg protein,
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saline and LMWH groups but significantly elevated in the
abciximab and tPA groups compared with the saline con-
trols (P  .05) (Fig 6).
Day 14 results. At day 14, the LMWH-treated group
Fig 5. Monocyte chemotactic protein-1 (MCP-1) levels in saline
control and treatment rats 1, 4, and 14 days after pulmonary
embolism. Graph shows the effect of treatment with saline, low-
molecular-weight heparin (LMWH), abciximab, and tissue plas-
minogen activator (tPA) on pulmonary tissue levels of MCP-1.
Saline, n 18; LMWH, n 10; abciximab, n 10; and tPA, n
12 for day 1. Saline, n 21; LMWH, n 10; abciximab, n 10;
and tPA, n  10 for day 4. Saline, n  24; LMWH, n  12;
abciximab, n 10; and tPA, n 9 for day 14. *P .05 compared
with saline controls for day 1. #P .05 compared with saline controls
for day 4. ^P .05 compared with saline controls for day 14.
Fig 6. Pulmonary artery intimal hyperplasia (PAIH) in rat treat-
ment groups. The effects of treatment with saline, low-molecular-
weight heparin (LMWH), abciximab, and tissue plasminogen ac-
tivator (tPA) on rat PAIH 4 and 14 days after treatment. LMWH
significantly reduced IH at day 14 compared with saline control. At
day 4, abciximab and tPA groups had significantly more IH than
the day 4 saline control.exhibited significantly lower levels of IL-13 with in the tissueof the affected lung compared with saline control rats (P 
.001) (Fig 4). IL-13 levels were elevated by 25% compared
with saline controls in the abciximab- and tPA-treated
groups (P  .05). MCP-1 levels at this time point were
similar between the saline, abciximab, and tPA groups.
However, LMWH-treated rats had significantly lower
MCP-1 levels compared with saline-treated rats (P .001)
(Fig 5). TGF- levels were 38% lower in the tPA-treated
group at day 14 compared with the saline control group
(P  .027) and elevated by 28% in the LMWH-treated
group (P  .007). TGF- levels in the abciximab-treated
group were similar to the saline control group (Fig 7).
PAIH was decreased by 54% in the LMWH-treated group
(P  .015), but the abciximab and tPA treatment groups
were similar to controls (Fig 3). Total lung collagen levels
at day 14 ranged from amean of 14 to 35g/mg of protein
and were not significantly different between treatment
groups (data not shown).
Cell count results. The number positive ED-1 and
smooth muscle -actin cells within the affected pulmonary
arteries of rats treated with LMWH, abciximab, and tPA
were similar compared with PE controls. The only signifi-
cant difference was that tPA-treated rats had more ED-1–
positive staining cells within the PA wall compared with
saline controls at day 1 (148  19 vs 47  17 cells/area,
tPA vs control, P  .029). At day 14, only abciximab-
treated rats had significantly more smooth muscle -actin–
positive cells within the PA wall than saline controls (157
11 vs 133  9 cells/area, P  .047).
Fig 7. Transforming growth factor- (TGF-) levels in saline
control and treatment rats 1, 4, and 14 days after pulmonary
embolism. Graph shows effect of treatment with saline, low-
molecular-weight heparin (LMWH), abciximab, and tissue plas-
minogen activator (tPA) on pulmonary tissue levels of TGF-.
Saline, n 18; LMWH, n 10; abciximab, n 10; and tPA, n
12 for day 1. Saline, n 21; LMWH, n 10; abciximab, n 10;
and tPA, n  10 for day 4. Saline, n  24; LMWH, n  12;
abciximab, n 10l and tPA, n 9 for day 14. *P .05 compared
with saline controls for day 1. #P .05 compared with saline controls
for day 4; ^P .05 compared with saline controls for day 14.Effect of pulmonary embolism on the contralateral
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nary inflammation occurred after PE and its treatment, the
same measures of inflammation were analyzed in the con-
tralateral, unaffected lungs of all rat groups in this model.
As with the affected pulmonary tissue, IL-13 levels at day 1,
4, and 14 were significantly lower in the contralateral lungs
of rats treated with LMWH (day 1: 17 4 ng/mL vs 87
9 ng/mL, n  10, P  .001; day 4: 22  6 ng/mL vs
103  10 ng/mL, n  10, P  .001; day 14: 36  2
ng/mL vs 133 17 ng/mL, n 12, P .001 for LMWH
vs saline, n  14, 30, and 24 at days 1, 4, and 14,
respectively). IL-13 levels at day 14 were significantly ele-
vated in the contralateral lungs in the abciximab group
(140 11 ng/mL, n 9) and in the tPA group (147 16
ng/mL, n  7) compared with saline controls (113  17
ng/mL, n  24; both P  .01).
MCP-1 levels were significantly lower in the contralat-
eral lungs of rats treated with tPA at day 1 compared with
saline-injected rats (31  4 ng/mL, n  12 vs 88  15
ng/mL, n  8, P  .001). MCP-1 levels did not differ
between groups at day 4; however, at day 14, the LMWH
group had lower levels of MCP-1 compared with the saline
rats (12  0.8 ng/mL, n  12 vs 32  4 ng/mL, n  20,
respectively, P  .001).
TGF- levels in the contralateral lungs of all groups
were similar at day 1. Interestingly, lung TGF- levels were
markedly elevated in the LMWH and tPA groups com-
pared with saline PE controls (271  48 ng/mL, n  10;
258  29 ng/mL, n  10 vs 183  21 ng/mL, n  10;
both P  .05) at day 4. Abciximab-treated rats had lower
levels of TGF- (103 18 ng/mL; n 10) compared with
saline-treated rats (P  .024) at day 4. At day 14, TGF-
levels remained significantly elevated in LMWH-treated
rats (223 9 ng/mL, n 12 vs 161 18 ng/mL, n 24;
P  .026), but no differences in levels in the rats treated
with tPA or abciximab remained at day 14.
Total collagen levels were similar in the contralateral
lungs of all groups at day 14. No significant IH was found
in the contralateral PAs of rats in any treatment group at
any time point compared with control rats (data not
shown). Counts of ED-1 and smooth muscle -actin-
positive cells were also similar in all unaffected lungs in all
groups compared with the saline control group at days 1, 4,
and 14 (data not shown).
DISCUSSION
PE remains a significant cause of death in hospitalized
patients.1 Increased awareness of venous thromboembo-
lism risk factors and prophylaxis is now a Center for Medi-
care Services quality process variable. Better understanding
of the molecular and cellular pathophysiology may allow
improved therapies to lessen the early mortality and long-
term morbidity of PE. Although experimental, the current
report suggests that persistent PA occlusion may be more
injurious than the contents of the lysing thromboembo-
lism, and that the current standard of care for PE treatment
may be better than other agents for preventing delayed PA
injury. It is also likely the observed responses are a result oflocal humoral and globally neuronal-mediated effects from
the PA stretch and hypoxemia.
The PA and parenchymal response to the persistent
stretch of a silicone plug was striking, with marked PAIH in
the affected lung through 21 days, and elevation of IL-13
levels in the contralateral lung. Although our prior report10
suggested that the formed thrombus may primarily direct
the PA and lung responses via MCP-1, it is clear that the
occlusion of the PA also increases local MCP-1, as observed
on day 4 and 14. Although not identical to our model,
styrene microsphere embolization to the PA produced an
intense inflammatory response,16 including elevation of
CCR2, the primary receptor for MCP-1. MCP-1 has been
shown in histologic sections of patients with pulmonary
hypertension secondary to PE and is a direct monocyte
chemoattractant.17
Monocytes were not significantly altered by the silicone
embolus insult or the different anticoagulant treatments. This
suggests that the local environment may direct monocyte
activity but not necessarily increase the overall number.More-
over, the current data support that hypoxic pulmonary
vasoconstriction may play a role in the observed PAIH, as
the silicone is inert and would not be a direct source of
MCP-1 or IL-13. Modulation of PAIH secondary to per-
sistent pulmonary vasoconstriction is well supported18 but
is speculative in this model, because we did not directly
measure PA pressures.
Rapid administration of LMWHwas the most effective
agent for reducing both PAIH and, possibly, lung injury
despite no gross acceleration of venous thromboembolic
resolution in this model at the time points examined in
this study. The affected and contralateral lung tissue of
LMWH-treated rats also had lower profibrotic growth
factor levels of IL-13 and MCP-1 than control PE rats,
suggesting an effect of the regional pulmonary systemic
injury after PE.
The unique anti-inflammatory and antifibrotic effects
of LMWH may be due to its effect on cell adhesion mole-
cules. For example, in a rat model of DVT, both P-selectin
inhibition and LMWH equally inhibited vein wall fibrotic
injury.19 Similarly, LMWH has direct anti-inflammatory
properties independent of its anticoagulant effects with less
vein wall inflammatory cellular influx after DVT in a rat
model.20 Interestingly, LMWH was associated with in-
creased levels of TGF-, a cytokine associated with lung
fibrosis after pulmonary injury in other models.21,22 How-
ever, these are direct parenchymal chemical injury models
and different than a PE-induced injury. Further, TGF- has
known anti-inflammatory properties, depending on the
local environment, and has antiproliferative effects on some
cell types.21 Our data, however, do not definitely prove a
direct cause-and-effect relationship between these media-
tors and the different phenotypic responses observed.
These experiments also suggest an important role for
IL-13 in the pathophysiology of acute PE. Consistent
with the observed PAIH effects, IL-13 is a profibrotic
cytokine that causes fibroblast and smooth muscle cell
proliferation and can promote organ fibrosis indepen-
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fibroblast proliferation, increase extracellular matrix pro-
duction, and cause decreased production of vasorelaxant
mediators such as prostaglandin E2.
24,25 In a infectious
model of pulmonary injury, IL-13 directly stimulated
MCP-1 expression.26 Our data did not show this consis-
tent relationship and may be due to the timing of medi-
ator analysis. Despite marked differences in PAIH, no
difference in -actin–positively stained cells was ob-
served between the treatments, or between the silicone
and venous thromboemboli, and suggests that a profi-
brotic phenotype was promoted rather than fibroblast
proliferation. This observation is consistent with the
activities of both MCP-1 and IL-13.23,25
Treatments with tPA and abciximab were not associ-
ated with reduced PAIH development compared with con-
trol PE rats. In fact, both of these agents seemed to stimu-
late earlier PAIH than that which occurred in controls.
Although platelets are rich in growth factors, the lack of a
protective effect of abciximab suggests that the platelet may
have less of a role in promoting PAIH, perhaps because the
formed venous thromboembolus is fibrin rather than plate-
let rich. It is possible that abciximab may have stimulated
release of platelet-derived growth factor.27 Moreover, acti-
vated platelets increase local MCP-1 release from endothe-
lium,28 and lung levels of MCP-1 were significantly greater
on day 4 in abciximab-treated rats than in controls and the
other groups. None of the agents seemed to affect pulmo-
nary fibrosis within the time frame analyzed, although a
trend toward lesser total lung collagen was noted with all
treatments.
Limitations of the current study include only single-
agent dosing. This was done in part for logistic reasons, and
our data may underestimate a greater effect with dosing
every day or more frequently. The PE themselves lysed at
similar rates (all by day 4), however, and our data support
that the effects of these agents are independent of throm-
bus resolution. This observation is limited in that thrombus
lysis may have been accelerated and occurred earlier in the
treatment groups at a time point between our day 1 and day
4 study groups, and that thrombusmight have been present
around the silicone embolus for some duration of time,
although this was not noted at harvest. Also, the rat seems to
have a survival that is greater than humans, in part because it
lacks comorbid cardiac and pulmonary disease, and direct
extrapolation of our findings should be done with caution.
We also did not determine the cellular source of these
mediators and cannot comment on whether these mediator
responses were primarily from the parenchyma or the PAs.
This will require further study.
Finally, whether the beneficial effect of certain treat-
ments such as LMWHwould remain with treatment several
hours after PE is unknown. The fact that the rats were
rapidly dosed may also not reflect the typical clinical situa-
tion, but does suggest that rapid therapy maybe associated
with better long-term outcomes.CONCLUSION
The data we have presented suggest a complex inter-
play of both affected and contralateral lung profibrotic
mediators that may be attenuated with rapid LMWH ther-
apy. Conversely, persistent PA obstruction seems more
important in promoting pulmonary injury than does the
release of venous thromboembolism mediators. Although
other agents such as tPA are clinically beneficial in certain
cases of massive PE,29 this agent and abciximab are not as
effective against later PA injury, and in fact, may stimulate
PAIH.
We appreciate the helpful suggestions of Lazar Green-
field, MD, who conceptualized the rat PE model used in
this study.
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